Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis

被引:130
|
作者
Amick, Halle R. [1 ]
Gartlehner, Gerald [2 ,3 ]
Gaynes, Bradley N. [4 ]
Forneris, Catherine [4 ]
Asher, Gary N. [5 ]
Morgan, Laura C. [2 ]
Coker-Schwimmer, Emmanuel [1 ]
Boland, Erin [2 ]
Lux, Linda J. [2 ]
Gaylord, Susan [6 ]
Bann, Carla [2 ]
Pierl, Christiane Barbara [3 ]
Lohr, Kathleen N. [2 ]
机构
[1] Univ N Carolina, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA
[2] RTI Int, Res Triangle Pk, NC 27709 USA
[3] Danube Univ, Dept Evidence Based Med & Clin Epidemiol, A-3500 Krems, Austria
[4] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Dept Phys Med & Rehabil, Chapel Hill, NC 27599 USA
来源
基金
美国医疗保健研究与质量局;
关键词
PRIMARY-CARE PATIENTS; TREATMENT PREFERENCES; TREATING DEPRESSION; ANXIETY DISORDERS; RANDOMIZED-TRIAL; PSYCHOTHERAPY; MEDICATION; PHARMACOTHERAPY; HEALTH; ACTIVATION;
D O I
10.1136/bmj.h6019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
STUDY QUESTION What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults? METHODS This was a systematic review including qualitative assessment and meta-analyses using random and fixed effects models. Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature were searched from January1990 through January 2015. The 11 randomized controlled trials included compared a second generation antidepressant CBT. Ten trials compared antidepressant monotherapy with CBT alone; three compared antidepressant monotherapy with antidepressant plus CBT. SUMMARY ANSWER AND LIMITATIONS Meta-analyses found no statistically significant difference in effectiveness between second generation antidepressants and CBT for response (risk ratio 0.91, 0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change in 17 item Hamilton Rating Scale for Depression score (weighted mean difference, -0.38, -2.87 to 2.10). Similarly, no significant differences were found in rates of overall study discontinuation (risk ratio 0.90, 0.49 to 1.65) or discontinuation attributable to lack of efficacy (0.40, 0.05 to 2.91). Although more patients treated with a second generation antidepressant than receiving CBT withdrew from studies because of adverse events, the difference was not statistically significant (risk ratio 3.29, 0.42 to 25.72). No conclusions could be drawn about other outcomes because of lack of evidence. Results should be interpreted cautiously given the low strength of evidence for most outcomes. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with CBT, and many of the included trials had methodological shortcomings that may limit confidence in some of the findings. WHAT THIS STUDY ADDS Second generation antidepressants and CBT have evidence bases of benefits and harms in major depressive disorder. Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
    Masaki Kato
    Hikaru Hori
    Takeshi Inoue
    Junichi Iga
    Masaaki Iwata
    Takahiko Inagaki
    Kiyomi Shinohara
    Hissei Imai
    Atsunobu Murata
    Kazuo Mishima
    Aran Tajika
    Molecular Psychiatry, 2021, 26 : 118 - 133
  • [32] Comparative Risk for Harms of Second Generation AntidepressantsA Systematic Review and Meta Analysis
    Gerald Gartlehner
    Patricia Thieda
    Richard A. Hansen
    Bradley N. Gaynes
    Angela DeVeaugh-Geiss
    Erin E. Krebs
    Kathleen N. Lohr
    Drug Safety, 2008, 31 : 851 - 865
  • [33] Predictors of treatment outcome in cognitive behavioral therapies for patients with somatic symptom disorder: A systematic review and meta-analysis
    Sarter, Lena
    Heider, Jens
    Kirchner, Lukas
    Witthoeft, Michael
    Rief, Winfried
    Kleinstauber, Maria
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2021, 28 (SUPPL 1) : S187 - S187
  • [34] Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis
    Wagner, Gernot
    Schultes, Marie-Therese
    Titscher, Viktoria
    Teufer, Birgit
    Klerings, Irma
    Gartlehner, Gerald
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 228 : 1 - 12
  • [35] Third generation cognitive-behavioral therapies for major depressive disorder- a literature review
    Vasile, D.
    Vasiliu, O.
    Vasiliu, D.
    EUROPEAN PSYCHIATRY, 2021, 64 : S325 - S325
  • [36] IMMEDIATE VS. EXTENDED RELEASE SECOND-GENERATION ANTIDEPRESSANTS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER - A SYSTEMATIC REVIEW
    Nussbaumer, B.
    Morgan, L. C.
    Reichenpfader, U.
    Greenblatt, A.
    Hanson, R. A.
    Van Noord, M. G.
    Lux, L.
    Gaynes, B. N.
    Gartlehner, G.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [37] The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis
    Berardelli, Isabella
    Rogante, Elena
    Formica, Federico
    Iannazzo, Riccardo
    Mammoliti, Attilio Valerio
    Riccioni, Raffaele
    Veizi, Skender
    Mcintyre, Roger S.
    Pompili, Maurizio
    JOURNAL OF PSYCHOPHARMACOLOGY, 2025, 39 (02) : 92 - 105
  • [38] Cognitive Functioning in the First-Episode of Major Depressive Disorder: A Systematic Review and Meta-Analysis
    Ahern, Elayne
    Semkovska, Maria
    NEUROPSYCHOLOGY, 2017, 31 (01) : 52 - 72
  • [39] Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis
    Ahern, Elayne
    White, Jessica
    Slattery, Eadaoin
    NEUROPSYCHOLOGY REVIEW, 2024, 35 (1) : 1 - 34
  • [40] The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder A Systematic Review and Meta-Analysis
    Gartlehner, Gerald
    Thaler, Kylie
    Hansen, Richard A.
    Gaynes, Bradley N.
    DRUG SAFETY, 2009, 32 (12) : 1159 - 1173